ClearPoint Neuro, Inc. (CLPT)

Over the past six months, ClearPoint Neuro's stock price has been impacted by several events. In November 2025, the company completed the acquisition of IRRAS, but the stock experienced a negative reaction despite positive earnings. In December 2025, retail investors saw an increase in the value of their holdings. In January 2026, ClearPoint Neuro announced preliminary unaudited fourth-quarter and full-year 2025 revenue and received EU MDR Certification, while UniQure's stock tripled, positively influencing ClearPoint shares. In March 2026, the company reported record 2025 revenue but projected lower-than-expected 2026 revenue guidance, leading to stock declines and a missed EPS estimate. In April 2026, technical indicators showed mixed signals, and the stock price reflected a decline over the preceding year.

There is no direct information available regarding the seasonality of demand for ClearPoint Neuro's products and services, but historically, buying CLPT stock in January has shown the highest probability of a positive return, whereas August has the lowest probability.

ClearPoint Neuro, Inc. is a medical device company specializing in technologies that enable precise navigation for procedures in the brain and spine. The company's business model integrates clinical products with preclinical development services for controlled drug and device delivery to the central nervous system. Its flagship product is the ClearPoint Neuro Navigation System, which facilitates minimally invasive surgical procedures in the brain under image guidance. The company's offerings are structured around four key growth areas: pre-commercial biologics and drug delivery, neurosurgery navigation, laser therapy and access, and intracranial fluid management.

ClearPoint Neuro engages with healthcare and research centers across North America, Europe, Asia, and South America, collaborating globally with pharmaceutical and biotechnology companies, academic centers, and contract research organizations. The company is actively working to expand its global commercial footprint and secure international regulatory approvals in regions such as Canada, Hong Kong, and Taiwan. While it has a pre-clinical contract research facility in Torrey Pines, and expanded its office and lab space in San Diego, California, the majority of its revenue and system installations are currently concentrated in the U.S.

ClearPoint Neuro's brand name has become synonymous with precision-guided neurosurgery, positioning the company as a key enabler in advancing minimally invasive therapies. Analyst sentiment is mixed, with consensus ratings varying between "Hold" and "Strong Buy". The company's reputation among investors focused on financial stability may be impacted by its history of revenue growth coupled with consistent net losses. Recent lowered revenue guidance and a miss on EPS have also contributed to stock declines, negatively affecting brand perception.

ClearPoint Neuro, Inc. has a diverse ownership structure. Institutional investors hold approximately 38.17%, 41%, or 30.08% of the stock. Major institutional owners include BlackRock, Inc. and Vanguard Group Inc. Individual owners, including insiders, hold about 25.86%, 3.29%, or 6.97% of the stock, with Bruce C. Conway being the largest individual shareholder. Retail investors collectively hold a significant portion, estimated at 35.97%, 51%, or 71.19%. Public companies are reported to own 3.0% or 8.51%.